Inclusion body myositis (IBM) is caused by a combination of immune system dysfunction and degenerative processes inside muscle cells, though no single trigger has been identified. It is the most common acquired muscle disease in people over 50, affecting roughly five to nine people per million adults. What makes IBM unusual among inflammatory muscle diseases is that both the immune system and the muscle cells themselves appear to malfunction simultaneously, and researchers still debate which problem comes first.
Two Processes Happening at Once
Most experts describe IBM as a disease driven by two parallel problems: an autoimmune attack on muscle fibers and a buildup of toxic proteins inside those fibers. These are sometimes called the inflammatory and degenerative components, and they likely feed off each other.
On the inflammatory side, a specific type of immune cell invades healthy muscle tissue. These cells latch onto muscle fibers and damage them directly. Under a microscope, you can see immune cells surrounding and invading fibers that aren’t yet dying on their own, a pattern called autoaggressive inflammation.
On the degenerative side, muscle cells lose their ability to clear out old or misfolded proteins. Normally, cells break down and recycle damaged proteins through two cleanup systems. In IBM, both of these systems falter. The result is a buildup of protein clumps (called inclusion bodies, which give the disease its name) containing more than 50 different proteins. Some of these, like amyloid precursor protein and phosphorylated tau, are the same proteins that accumulate in Alzheimer’s disease, which has long intrigued researchers studying the overlap between IBM and neurodegeneration.
The Immune Attack on Muscle
The immune cells doing the most damage in IBM are a subset of white blood cells designed to kill virus-infected or cancerous cells. In IBM, these cells mistakenly target healthy muscle fibers. Part of the problem is that IBM muscle fibers display a surface molecule they normally wouldn’t, essentially putting up a flag that attracts the immune system’s attention.
Genome-wide association studies have confirmed that genes involved in presenting molecules to immune cells are the strongest genetic risk factor for IBM. This means the disease is, at least in part, a case of the immune system being genetically primed to misidentify muscle tissue as a threat. An antibody called anti-cN1A, which targets an enzyme found inside all cells, is detected in a meaningful proportion of IBM patients with high specificity, further supporting the autoimmune component. Still, IBM does not respond to immunosuppressant medications the way other inflammatory muscle diseases do, which is one of the central puzzles of the condition.
Genetic Risk Factors
IBM is not inherited in a straightforward way, but certain gene variants dramatically increase risk. The strongest association is with a gene variant called HLA-DRB1*03:01, which raises the odds of developing IBM more than eightfold. Other variants in the same gene family increase risk by two to sixfold. In people of European descent, a specific cluster of gene variants known as the 8.1 ancestral haplotype is particularly associated with the disease. Interestingly, this same cluster is not linked to IBM risk in Japanese populations, suggesting that genetic susceptibility varies by ethnicity.
At least one gene variant, HLA-DRB1*15:01, appears to be protective, roughly halving the risk of IBM. These genetic findings point strongly toward the immune system’s role in the disease, since the implicated genes all relate to how the body identifies and responds to foreign or abnormal proteins.
Mitochondrial Damage in Muscle Fibers
Mitochondria, the structures inside cells that generate energy, are significantly damaged in IBM muscle. Biopsies show that 2% to 15% of muscle fibers in IBM patients have lost the ability to produce energy normally through a key enzyme in the energy-production chain. The underlying cause is damage to mitochondrial DNA: IBM muscle contains roughly 42% of the normal amount of mitochondrial DNA, and what remains carries far more deletions and duplications than healthy muscle. The average level of these mutations runs about 10% in IBM muscle compared to just 1% in controls.
These mitochondrial defects create segments of energy-starved muscle fiber, sometimes stretching more than a millimeter in length. Whether the mitochondrial damage is a cause of IBM or a consequence of the immune attack and protein buildup remains unclear, but it contributes to the progressive weakness that defines the disease.
Possible Viral Triggers
Several viruses have been investigated as potential triggers for IBM, including HIV, hepatitis C, and human T-lymphotropic virus type 1 (HTLV-1). IBM patients have a higher prevalence of hepatitis C and HTLV-1 infection than the general population, and many HIV-positive patients with inflammatory muscle disease eventually develop features consistent with IBM.
The viruses themselves don’t appear to infect muscle cells directly. Instead, viral material is found inside the immune cells and inflammatory cells that invade the muscle. One theory is that chronic viral infection accelerates immune cell aging, pushing certain immune cells into a hyperactive, dysfunctional state that then drives the attack on muscle tissue. This would explain why IBM is a disease of older adults and why certain chronic infections seem to increase risk.
Which Muscles Are Affected and Why It Matters
IBM targets specific muscles in a pattern that helps distinguish it from other muscle diseases. The quadriceps (front of the thigh), the deep finger flexors in the forearm, and the inner calf muscle are consistently the most affected. This means early symptoms often include difficulty gripping objects, trouble climbing stairs, and frequent falls. Lower limbs are hit harder than upper limbs, and the weakness tends to be worse on the front of the legs than the back.
The disease progresses slowly, typically over years rather than months, and it primarily strikes people over 45. Unlike other inflammatory muscle diseases where treatment can halt or reverse damage, IBM’s degenerative component means that even aggressive immune-suppressing therapy fails to stop progression, which is why understanding the full range of causes is so critical to developing effective treatments.
How IBM Is Confirmed
Because IBM’s causes span both inflammation and degeneration, diagnosis requires evidence of both. A muscle biopsy is the gold standard, and pathologists look for three hallmark features: immune cells invading non-dying muscle fibers, rimmed vacuoles (tiny holes in muscle fibers bordered by debris), and protein aggregates that glow under special staining. However, up to 25% of people with clinical IBM don’t show rimmed vacuoles or protein deposits on biopsy, which can lead to misdiagnosis as a different inflammatory muscle disease and unnecessary treatment with steroids or immune-suppressing drugs.
The anti-cN1A antibody blood test can help resolve uncertain cases, particularly when a biopsy is inconclusive. Its high specificity means that a positive result strongly supports an IBM diagnosis, even if the biopsy findings are incomplete.